Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

212
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
212
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

237
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
237
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.8K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

6.5K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.5K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of the Microbiome in the Development of an Autoimmune Reaction in Rheumatoid Arthritis.

Frontiers in bioscience (Scholar edition)·2026
Same author

NKG2D as a molecular link between epithelial stress and immune activation in Crohn's disease: therapeutic implications.

Cellular and molecular biology (Noisy-le-Grand, France)·2026
Same author

Retraction notice to "Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms" [Biomedicine & Pharmacotherapy 146 (2022) 112442].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

An overview of the role of the gut microbiota in rheumatoid arthritis.

Microbiome research reports·2026
Same author

Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes.

Virologica Sinica·2026
Same author

Analysis of the use of monoclonal antibodies in the treatment of Crohn's disease.

Antibody therapeutics·2026

Related Experiment Video

Updated: Aug 7, 2025

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
10:08

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders

Published on: August 25, 2022

3.0K

Epac as a tractable therapeutic target.

Hasan Slika1, Hadi Mansour1, Suzanne A Nasser2

  • 1Department of Pharmacology and Toxicology, American University of Beirut, Beirut, P.O. Box 11-0236, Lebanon.

European Journal of Pharmacology
|March 9, 2023
PubMed
Summary
This summary is machine-generated.

Cyclic adenosine monophosphate (cAMP) signaling involves Epac, a key mediator in diseases like cancer and diabetes. Epac modulators offer potential for developing targeted and effective treatments for various conditions.

Keywords:
CancerCardiovascular diseaseEpacPharmacotherapeuticscAMP

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

570
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Related Experiment Videos

Last Updated: Aug 7, 2025

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
10:08

The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders

Published on: August 25, 2022

3.0K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

570
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Pharmacology

Background:

  • Cyclic adenosine monophosphate (cAMP) is a crucial secondary messenger, with the cAMP-protein kinase A (PKA) pathway being the first discovered signaling cascade.
  • Exchange protein directly activated by cAMP (Epac) has emerged as a significant mediator of cAMP actions.
  • Epac plays a role in numerous pathophysiological processes and contributes to diseases including cancer, cardiovascular disease, diabetes, and neurological disorders.

Purpose of the Study:

  • To provide an in-depth analysis of Epac's structure, distribution, subcellular localization, and signaling mechanisms.
  • To explore the potential of Epac as a therapeutic target for various diseases.
  • To discuss the design of specific and safe Epac agonists and antagonists for pharmacotherapeutics.

Main Methods:

  • Structural analysis of Epac.
  • Investigation of Epac's distribution and subcellular compartmentalization.
  • Elucidation of Epac signaling pathways.

Main Results:

  • Epac's characteristics can be leveraged to design targeted therapeutic agents.
  • Epac modulators show promise for treating a wide range of diseases.
  • A portfolio of specific Epac modulators, including their discovery and clinical relevance, is presented.

Conclusions:

  • Epac is a critical mediator in diverse pathophysiological processes, highlighting its therapeutic potential.
  • Epac modulators offer unique advantages for developing novel treatments.
  • Understanding Epac's mechanisms is key to designing effective pharmacotherapeutics for diseases like cancer, diabetes, and cardiovascular conditions.